Cao et al. have conducted trial test using lopinavir-ritonavir drugs for COVID-19 patients. They found that lopinavir-ritonavir treatment failed to significantly accelerate clinical improvement, reduce mortality, diminish throat viral RNA detectability in patients with serious COVID-19. In case of the severe COVID-19 adult patients, no benefit was observed with lopinavir-ritonavir treatment in  comparison to the standard care group.  Such study has found that lopinavir-ritonavir does not seem to be effective for COVID-19 patients and these combinations has produced more side effects.